Pancreatic cancer survival edges up—as screening strategies emerge

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society’s Cancer Facts & Figures 2023, released last week, reports that the five-year survival rate for pancreatic cancer is now 12%, an increase of one percentage point from last year.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Rosario Ligresti, MD
Chief, Division of Gastroenterology, John Theurer Cancer Center, Hackensack University Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Rosario Ligresti, MD
Chief, Division of Gastroenterology, John Theurer Cancer Center, Hackensack University Medical Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login